RxDoctor Payments Data

Katalin Pocsine, MD

Neurology · Wheat Ridge, CONPI 1326138801

Payments from drug & device makers

$30,826in general payments, 2019–2025

Across 1,358 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akcea Therapeutics, Inc.$8K
  • AbbVie$3K
  • Abbott$2K
  • EMD Serono, Inc.$2K
  • Biogen$1K
  • Pfizer$1K
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$5,69418%
  • Travel & lodging$2,5728%
  • Food & beverage$22,40173%
  • Education$1581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Akcea Therapeutics, Inc.33$7,633
AbbVie(2 entities)200$2,622
Abbott27$2,034
EMD Serono, Inc.84$1,568
Biogen105$1,491
Pfizer95$1,241
Novartis84$1,097
Lilly USA, LLC49$997
Amgen(2 entities)59$812
Argenx US, Inc.27$687
Mallinckrodt Hospital Products Inc.38$604
Bristol Myers Squibb40$562
Lundbeck LLC28$556
Genentech USA, Inc.25$556
Sanofi27$547
Neurocrine Biosciences, Inc.32$526
AstraZeneca(2 entities)26$499
SK Life Science, Inc.21$473
UCB, Inc.24$451
Amneal Pharmaceuticals LLC28$439
Teva Pharmaceuticals USA, Inc.23$396
MDD US Operations, LLC18$343
Tanabe Pharma America, Inc.17$324
Alnylam Pharmaceuticals Inc.13$291
TG Therapeutics, Inc.12$249
Biohaven Pharmaceutical Holding Company Ltd.23$247
Harmony Biosciences LLC10$211
Mallinckrodt Enterprises LLC16$200
Acadia Pharmaceuticals Inc9$167
Eisai Inc.7$145
Grifols USA, LLC8$144
Kyowa Kirin, Inc.8$140
Biohaven Pharmaceuticals, Inc.15$136
Johnson & Johnson(2 entities)6$127
Neurelis, Inc.7$126
Avanir Pharmaceuticals, Inc.6$124
Adamas Pharmaceuticals, Inc.6$119
E.r. Squibb & Sons, L.L.C.7$118
Boston Scientific6$114
Scilex Pharmaceuticals Inc.6$110
CSL Behring5$103
Vanda Pharmaceuticals Inc.4$101
Assertio Therapeutics, Inc.6$98
Supernus Pharmaceuticals, Inc.6$83
GE HealthCare3$78
Sunovion Pharmaceuticals Inc.3$76
Avadel CNS Pharmaceuticals, LLC3$75
Medtronic(2 entities)4$74
Merz Pharmaceuticals, LLC4$74
Otsuka America Pharmaceutical, Inc.3$71
Acorda Therapeutics, Inc3$65
Banner Life Sciences, LLC4$63
Jazz Pharmaceuticals Inc.3$59
Cycle Pharmaceuticals Inc3$56
Axsome Therapeutics, Inc.2$46
Arbor Pharmaceuticals, Inc.3$42
Collegium Pharmaceutical, Inc.2$40
Catalyst Pharmaceuticals, Inc.2$38
Impel Pharmaceuticals Inc.2$35
C2n Diagnostics, LLC2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,826 in reported general payments places this provider in the 75th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$145,912
Medicare patients
354
Services billed
3,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$167,315
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$156,619
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5012$116,621
PanzygaImmun Glob G(Igg)-Ifas/Glycine15$100,480
BotoxOnabotulinumtoxina29$38,705
Nurtec OdtRimegepant Sulfate21$34,335
QuliptaAtogepant11$11,690
Dalfampridine ErDalfampridine11$9,743
Pregabalin129$5,606
Carbidopa-LevodopaCarbidopa/Levodopa124$3,331
Modafinil11$3,319
Gabapentin133$2,775
Memantine Hcl77$2,348
Pyridostigmine Bromide17$1,367
Lamotrigine30$1,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$103$156,61913 claims
PfizerPanzyga, Nurtec Odt$1,241$134,81636 claims
AbbVieBotox, Qulipta$2,622$50,39540 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$439$1,36717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 334 neurology providers in Colorado.

Other neurology in Wheat Ridge

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →